What is analysed in this type of test?

Clopidogrel, a commonly prescribed antiplatelet medication, is analysed alongside CYP2C19 genotyping. This analysis determines how an individual's genetic makeup affects their ability to metabolise Clopidogrel.

What do the results mean?

The result indicates whether the individual is a normal metaboliser, rapid metaboliser, intermediate metaboliser, or poor metaboliser of Clopidogrel. This information helps healthcare providers tailor the treatment plan to the patient's specific genetic profile.
 

Why is the test performed?

The analysis is crucial for optimising the effectiveness and safety of Clopidogrel therapy. By understanding how a patient metabolises the medication, healthcare providers can adjust the dosage accordingly, minimising the risk of adverse reactions and ensuring optimal therapeutic outcomes.
 

When should the test be performed?

CYP2C19 genotyping is typically conducted before initiating Clopidogrel therapy or when assessing the response to ongoing treatment. It can also be useful in cases of treatment failure or adverse reactions.
 

What type of sample is required?

A blood sample is required for CYP2C19 genotyping. This sample is usually collected through a simple blood draw.
 

Is any pre-preparation necessary?

Generally, no specific pre-preparation is required before obtaining the blood sample for CYP2C19 genotyping. Patients can typically undergo the test without any special dietary or lifestyle modifications.
 

How is the sample used?

The results of CYP2C19 genotyping guide healthcare providers in determining the appropriate Clopidogrel dosage for each patient. For example, individuals with reduced metabolising capacity may require lower doses to achieve the desired therapeutic effect, while those with increased metabolising capacity may need higher doses.
 

What are the normal values?

Normal values vary based on the specific genetic variants identified through genotyping. These values are categorised into different metaboliser types: normal, rapid, intermediate, and poor metabolisers.
 

What does it mean to have altered values?

Altered values indicate deviations from the standard metabolic activity. For instance, poor metabolisers may have significantly reduced Clopidogrel metabolism, leading to decreased drug effectiveness and potentially increased risk of adverse events.
 

CYP2C19 genotyping results

This table summarises the different genotypes identified through CYP2C19 genotyping, their corresponding metaboliser types, and the interpretation of their metabolic activity in relation to Clopidogrel therapy.